Europe moots Nanotech Action Project
This article was originally published in Clinica
Executive Summary
The European Commission will examine and, where appropriate, propose adaptations to EU regulations for nanotechnology products in the context of its Nanotechnology Action Plan for Europe. It also intends to develop a new framework for the risk assessment of nanotechnologies in general, developing terminology, guidelines, models and standards, Didier Bouis, the executive in charge of looking into the regulation of all areas of nanotechnology within the European Commission's Directorate General for Enterprise and Industry told the London nanotechnology conference on October 27.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.